The report provides a detailed analysis essential for establishing a Levonorgestrel production plant. It encompasses all critical aspects necessary for Levonorgestrel production, including the cost of Levonorgestrel production, Levonorgestrel plant cost, Levonorgestrel production costs, and the overall Levonorgestrel production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Levonorgestrel production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Levonorgestrel is a synthetic steroid hormone used as an active pharmaceutical ingredient in various contraceptive products, such as emergency contraception tablets, oral contraceptives, and hormone-releasing intrauterine devices (IUDs) designed for long-term birth control lasting 3 to 5 years. It is utilised in emergency contraception following unprotected sex or contraceptive failure. It also functions as an important component in combination with birth control pills alongside oestrogen to suppress ovulation. Additionally, Levonorgestrel delivers hormones via IUDs that prevent pregnancy and help manage heavy or painful menstrual periods.
Moreover, it is employed in the treatment of menstrual disorders, endometriosis, and endometrial hyperplasia. In pharmaceutical production, Levonorgestrel is formulated into tablets (commonly in 0.75 mg doses), mixtures, and IUDs to enhance its dissolution rates and bioavailability through techniques such as micronisation and solid dispersions.
Levonorgestrel market growth is driven by rising global awareness of reproductive health, increasing unintended pregnancies, and demand for accessible emergency contraception. The preference for long-acting reversible contraceptives (LARCs) like hormone-releasing IUDs, over-the-counter availability of tablets, and expanding online sales channels boost its market growth.
Additionally, treatments for gynaecological disorders such as endometriosis, government initiatives for family planning, and innovations in formulations for better efficacy and reduced side effects contributes to its demand. Factors such as strict adherence to API purity, stability, particle size, and dissolution rate specifications to ensure efficacy and safety in pharmaceutical formulations influence industrial levonorgestrel procurement. Moreover, procurement is also affected where patent protections or licensing agreements govern Levonorgestrel API production and distribution.
Raw Material for Levonorgestrel Production
According to the Levonorgestrel production plant project report, the raw material for Levonorgestrel production includes methoxydienone.
Production Process of Levonorgestrel
The extensive Levonorgestrel production cost report consists of the following major industrial production process:
- Production via a two-step chemical synthesis: The production process of Levonorgestrel occurs through a two-step synthesis starting from methoxydienone. The first step involves nucleophilic addition of acetylene, often as lithium acetylide in liquid ammonia or THF at -50 degree Celsius to -55 degree Celsius to form the dienol ether intermediate. This is followed by acid hydrolysis using 20% H2SO4 in THF or HCl in methanol/water at 55-60 degree Celsius, yielding Levonorgestrel after isolation, purification via recrystallisation, and drying. Additionally, process optimisations, such as aprotic solvents and precise temperature control, enhance yield, purity, and GMP compliance for pharmaceutical API production.
Properties of Levonorgestrel
Levonorgestrel (C21H28O2, molecular weight 312.45 g/mol) is a white to off-white, odourless crystalline solid with a melting point of 235-237 degree Celsius, practically insoluble in water but highly lipophilic (log P 3.3-3.8) and soluble in organic solvents. It is a synthetic 19-nortestosterone progestin featuring a C3 ketone, C17β hydroxy, and C17α ethynyl group (InChIKey WWYNJERNGUHSAO-XUDSTZEESA-N), stable under refrigeration (2-8 degree Celsius). These properties support its use in hydrophobic pharmaceutical formulations like tablets and IUDs.
